NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute has struck a collaborative research agreement with Ventana Medical Systems to study new biomarkers for use in treating pancreatic cancer, Ventana said today.
TGen and Roche Group member Ventana plan to discover and develop diagnostic, prognostic, and drug biomarkers that can be used to detect the disease early in its course, and to develop better, personalized treatments.
Pancreatic cancer is the fourth leading cause of death from cancer in the US, with less than one in four patients surviving for more than a year. It is particularly deadly because there is a lack of tools for early detection and effective treatments for the disease, Ventana said.
TGen President and Research Director Jeffrey Trent said in a statement that the collaboration's goal is "to rapidly translate basic research findings into actionable targets."
TGen's research resources include a genome technology core, a center for computational bioscience, microarray technologies, and the Bio4D software system for managing biospecimens and clinical data. Ventana makes digital pathology and tissue-based diagnostic products, including companion diagnostic tests.